Overview
Innovative Medicines based on
ImmunoModulatory Biologics
-
Pipeline
-
Overview
We have adopted an accelerated R&D model for the innovative immunomodulatory antibody drug development utilizing our proprietary platform technology as well as in-licensing novel antibody assets.
| Item | Portfolio | Code | Indication | Target | Discovery | Early Development |
Clinical Development |
Remark | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development Strategy |
Target PoC | Screening | Candidate | Proof of Indication & Process Development |
Non-clinical | |||||||
| Pipeline | Autoimmune | IMB-101 | RA
(→ AD/HS/IBD etc) |
OX40L/TNFa
(BsAb) |
28.06.'23 : US IND Submission
28.07.'23 : US IND Clearance 13.12.'23 : First Subject First Dosing |
|||||||
| IMB-102 | Autoimmune
disease |
OX40L
(mAb) |
IND enabling study | |||||||||
| IMB-104 | - | mAb-ePENDY | Dong-A ST
Collaboration |
|||||||||
|
Immune Oncology
(Antibody) |
IMB-201 | Cancer | HLA-G
(ADC) |
ADC evaluation | ||||||||
| IMB-202 | Cancer | Nondisclosure | ||||||||||
|
Immune Oncology
(STAM) |
IMB-401 | Cancer | Nondisclosure | Novel Cancer Immunotherapy
→ Specific TCR Triggering agonist (ePENDY) |
||||||||
| IMB-402 | Cancer | Nondisclosure | Novel Cancer Immunotherapy
→ Specific TCR Triggering agonist (ePENDY) |
|||||||||
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
- President(CEO) : Gyongsik Ha
- 260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea